Evolution of Drug Survival with Biological Agents and Apremilast Between 2012 and 2018 in Patients with Psoriasis from the PsoBioTeq Cohort

Drug survival reflects treatment effectiveness and safety in real life. There is limited data on the variation of drug survival with the availability of systemic treatments with additional biological disease-modifying antirheumatic drugs (bDMARDs) or synthetic disease-modifying antirheumatic drugs (...

Descripción completa

Detalles Bibliográficos
Autores principales: BETTUZZI, Thomas, BACHELEZ, Hervé, BEYLOT-BARRY, Marie, ARLÉGUI, Hugo, PAUL, Carle, VIGUIER, Manuelle, MAHÉ, Emmanuel, BENETON, Nathalie, JULLIEN, Denis, RICHARD, Marie-Aleth, JOLY, Pascal, TUBACH, Florence, DUPUY, Alain, SBIDIAN, Emilie, CHOSIDOW, Olivier
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Society for Publication of Acta Dermato-Venereologica 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9631244/
https://www.ncbi.nlm.nih.gov/pubmed/34806759
http://dx.doi.org/10.2340/actadv.v101.566

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9631244/
https://www.ncbi.nlm.nih.gov/pubmed/34806759
http://dx.doi.org/10.2340/actadv.v101.566

Ejemplares similares